Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | APAF1 | O14727 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.43 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398779 | 0.79 | CYP2C19 (0.63) | KMT2AALDH1A1MAPTAPAF1HTT | |
| SCHEMBL9537813 | 0.77 | CA12 (0.44) | KMT2AALDH1A1MAPTRAB9AL3MBTL1 | |
| SCHEMBL9760981 | 0.75 | CYP2C9 (0.66) | KMT2AALDH1A1MAPTHTTRAB9A | |
| SCHEMBL7648203 | 0.75 | KDM4E (0.52) | KMT2AALDH1A1MAPTHTTELANE | |
| SCHEMBL10712200 | 0.74 | MCL1 (0.57) | KMT2AALDH1A1L3MBTL1ELANEESR2 | |
| SCHEMBL27845264 | 0.74 | ALDH2 (0.62) | KMT2AALDH1A1MAPTRAB9AL3MBTL1 | |
| SCHEMBL113091 | 0.73 | PDE10A (0.62) | KMT2AALDH1A1HTTMEN1PDE10A | |
| SCHEMBL1366099 | 0.73 | TACR3 (0.54) | KMT2AALDH1A1MEN1CYP2C9CYP2C19 | |
| SCHEMBL70004 | 0.72 | KDM4E (0.68) | KMT2AALDH1A1MEN1PDE10ACYP2C9 | |
| SCHEMBL29599456 | 0.72 | KDM4E (0.68) | KMT2AALDH1A1MEN1PDE10ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415373-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8415356-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| EP-2313391-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-12-26 | — | — | EP | disclosed |
| EP-2342182-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-11-14 | — | — | EP | disclosed |
| US-8242134-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-08-14 | — | — | US | disclosed |
| US-8173639-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| EP-2342182-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2011-07-13 | — | — | EP | disclosed |
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-25 | — | — | US | disclosed |
| WO-2010028655-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-18 | — | — | WO | disclosed |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5444042-A | Administering peptide ketoamides, peptide ketoacids, and peptide ketoesters | CORTEX PHARMACEUTICALS (US) | 1995-08-22 | — | — | US | disclosed |
| EP-0650368-A1 | USE OF CALPAIN INHIBITORS IN THE INHIBITION AND TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH INCREASED CALPAIN ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1995-05-03 | — | — | EP | disclosed |
| US-5324648-A | Anticoagulants; antitumor agents | GEORGIA TECH RESEARCH CORPORATION (US) | 1994-06-28 | — | — | US | disclosed |
| US-5306824-A | Enzyme inhibitors; purifying proteins | GEORGIA TECH RESEARCH CORPORATION (US) | 1994-04-26 | — | — | US | disclosed |
| WO-1994000095-A2 | USE OF CALPAIN INHIBITORS IN THE INHIBITION AND TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH INCREASED CALPAIN ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| US-5089633-A | Protease inhibitors, antiinflammatory agents | GEORGIA TECH RESEARCH CORPORATION (US) | 1992-02-18 | — | — | US | disclosed |
| US-5089634-A | Protease inhibitors, antiinflammatory agents, anticoagulants | GEORGIA TECH RESEARCH CORPORATION (US) | 1992-02-18 | — | — | US | disclosed |
| US-4711956-A | GRAMPOSITIVE, GRAMNEGATIVE BACTERIA | TPO "PHARMACHIM" (BG) | 1987-12-08 | — | — | US | disclosed |
| EP-0203216-A1 | Penicillin derivatives and process for their preparation | T P O "PHARMACHIM" (BG) | 1986-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | KMT2A 891/4885ALDH1A1 2399/4885MAPT 1473/4885 |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | KMT2A 1850/4885ALDH1A1 2304/4885MAPT 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.